Leukocyte Reduction with Arterial Line Filters
- Pulmonary Dysfunction is a Costly Complication of CPB Surgery
- Leukocytes Mediate Pulmonary Dysfunction
- Leukocyte Reducing Arterial Line Filters Selectively Remove Noxious Agents
- Leukocyte Reducing Arterial Line Filters Improve Pulmonary Function
- Leukocyte Reducing Effect Characterized
- The LeukoGuard® AL Offers Flexibility and Potentially Enhances Clinical Value
- Summary Of Evidence
Pulmonary Dysfunction is a Costly Complication of CPB Surgery
While actual costs of managing patient morbidity are not well known, patient charges appear to be a reasonable approximation of costs. Using basic assumptions about costs and charges, it is possible to develop some appreciation of hospital costs to manage this complication as shown in the accompanying table.
Table 1. Estimated Cost of Managing Pulmonary Failure following CPB
|Cost per 1,000|
Leukocytes Mediate Pulmonary Dysfunction
Figure 1. Leukocytes during CPB adapted from Gu8
Therefore, activated neutrophils are important in the cause of pulmonary dysfunction which, in its extreme form, may present as respiratory failure. This, in turn, could result in costly protracted ventilator time and increased length of stay in the hospital.
Leukocyte Reducing Arterial Line Filters Selectively Remove Noxious Agents
Leukocyte Reducing Arterial Line Filters Improve Pulmonary Function
Summary of Clinical Efficiency Leukoreduction During CPB
Leukocyte Reducing Effect Characterized
Figure 2. Neutrophils during bypass adapted from Silvay et al, 1997.17
The LeukoGuard® AL Offers Flexibility and Potentially Enhances Clinical Value
|The LeukoGuard® filter is a novel technological advancement. The LeukoGuard AL, not only affords uninterrupted filtration protection but may be used to employ leukocyte reduction strategically, toward the end of the bypass period, when neutrophilia predominates and coincides with pulmonary reperfusion. Any incidence of high line pressures associated with the use of the Pall LeukoGuard® filter may require the use of the filter bypass line. In order to ensure uninterrupted use, the latest version of LeukoGuard® (the LGAL) provides a filtration system complete with two filters; a conventional air-eliminating and microaggregate-reducing arterial line filter positioned proximal to a leukoreducing filter in one convenient package.|
Summary Of Evidence
- Taylor GJ, Mikell FL, Moses HW, et al: Determinants of hospital charges for coronary artery bypass surgery: the economic consequences of postoperative complications. Am J Cardiol 1990;65:309-313.
- Shapira N, Zabatino SM, Ahmed S, et al: Determinants of pulmonary function in patients undergoing coronary bypass operations. Ann Thor Surg 1990; 50:268-273
- Maggart M, Stewart S: The mechanisms and management of non-cardiogenic pulmonary edema following cardiopulmonary bypass. Ann Thorac Surg 1987; 43:231-236.
- Hedlund K: Pulmonary complications following cardiopulmonary bypass. Am Acad Cardiovasc Perfusion Newsletter, Fall, 1994; pp. 6-7.
- Kirklin JK: Prospects for understanding and eliminating the deleterious effects of cardiopulmonary bypass. Ann Thorac Surg 1991; 51:529-531.
- Allen S: The role of leucocytes in the systemic inflammatory response and the potential impact of leucocyte depletion. Cardiovasc Eng 1997; 2:34-54.
- Bulkley GB. Reactive oxygen metabolites and reperfusion injury: aberrant triggering of reticuloendothelial function. Lancet 1994; 344: 934-936.
- Gu YJ: Inhibition of the inflammatory response initiated during cardiopulmonary bypass [PhD Thesis]. Groningen, The Netherlands: University Hospital, 1992.
- Quiroga MM, Miyagishima R, Haendschen LC, et al: The effect of body temperature on leukocyte kinetics during cardiopulmonary bypass. J Thorac Cardiovasc Surg 1985; 90: 91-96.
- Thurlow PJ, Doolan L, Sharp R, et al: Studies of the effect of Pall leukocyte filters LG6 and AV6 on an in-vitro simulated extracorporeal circulatory system. Perfusion 1995; 10:291-300.
- Hurst T, Johnson D, Cujec B, et al: Depletion of activated neutrophils by a filter during cardiac valve surgery. Can J Anaesth 1997; 44:131-139.
- Palanzo DA, Manley NJ, Montesano RM, et al: Clinical evaluation of the LeukoGuard (LG-6) arterial line filter for routine open-heart surgery. Perfusion 1993; 8:489-496.
- Palanzo DA, Manley NJ. Cost effectiveness of using a leuko-depleting arterial line filter. Proc Amer Acad Cardiovasc Perfusion 1994; 15:124-127.
- Johnson D, Thomson D, Mycyk T, Burnbridge B, Mayers I. Depletion of neutrophils by filter during aortocoronary bypass surgery transiently improves postoperative cardiorespiratory status. Chest 1995; 107: 1253-1259.
- Coleman SM, Demastrie L. Leukocyte depletion reduces postoperative oxygen requirements. Ann Thorac Surg 1994; 58:1567-8.
- Gott JP, Cooper W, Schmidt F, et al: Documentation of risk neutralization for extracorporeal circulation in four limbed, 400 patient, risk stratified, prospective, randomized trial. Presented at the Southern Thoracic Surgical Association meeting, Nov 7, 1997; Naples, FL.
- Silvay G, Ammar T, VelaCantos L: Preservation of platelet reactivity with leukocyte reduction. Anesthesiology (1997) 87:A66.